The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Role of the SPA17-AXL Pathway in Melanoma Progression and the Antitumor Potential of SPA17-Targeted Vaccination

  • By

  • Lan Zhang

  • Mengshu You

  • Bin Yan

  • Jian Zhang

  • Yi Yao

  • Qingyan Zhang

  • Zuozhong Xie

  • Shixiang Wang

  • Qian Gao

  • September 9, 2026

Share

Clinical Report: The Role of the SPA17-AXL Pathway in Melanoma Progression

Overview

This study investigates the expression and role of SPA17 in melanoma, highlighting its association with poor prognosis. Additionally, it evaluates the potential of a SPA17-targeted peptide vaccine in restraining melanoma progression.

Background

Melanoma is a highly aggressive skin cancer with significant immunogenicity. Understanding the mechanisms behind melanoma progression and immune evasion is crucial for developing effective treatments. The identification of novel tumor antigens, such as SPA17, may provide insights into immunotherapy.

Data Highlights

FindingDetails
SPA17 ExpressionMarked upregulation in melanoma tissues, especially in metastatic lesions.
Prognostic ValueElevated SPA17 expression correlates with poor prognosis.
In Vitro EffectsSPA17 knockdown significantly inhibited melanoma cell migration.
In Vivo EffectsSPA17 depletion reduced tumor growth in a mouse model.
Immune ModulationIncreased intratumoral CD8+ T-cell infiltration with SPA17 knockdown.
Vaccine EfficacySPA17-targeting peptide vaccine restrained melanoma progression.

Key Findings

  • SPA17 is overexpressed in melanoma, particularly in metastatic lesions.
  • Higher SPA17 levels are linked to poor prognosis.
  • Knockdown of SPA17 inhibits melanoma cell migration and reduces tumor growth in vivo.
  • SPA17 positively regulates AXL expression.
  • SPA17-targeted vaccination enhances antitumor immune responses.

Clinical Implications

The findings indicate that SPA17 may serve as a prognostic biomarker in melanoma.

Conclusion

SPA17 plays a role in melanoma progression and immune evasion. Further clinical investigation is warranted.

Related Resources & Content

  1. The ASCO Post, 2020 -- Novel Treatment Strategies Under Study in Advanced Melanoma
  2. The ASCO Post, 2024 -- Illuminating a Potential Culprit in Melanoma Treatment Resistance
  3. The ASCO Post, 2016 -- Personalized Vaccines May Protect Patients With High-Risk Melanoma
  4. The ASCO Post, 2024 -- Report Sheds Light on Critical Pathway Responsible for Treatment Resistance in Melanoma
  5. NCCN Clinical Practice Guidelines In Oncology, 2026 -- Melanoma: Cutaneous, Version 2.2026
  6. New England Journal of Medicine, 2022 -- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
  7. Molecular Cancer -- AXL: shapers of tumor progression and immunosuppressive microenvironments
  8. Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology - PubMed
  9. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma | New England Journal of Medicine
  10. AXL: shapers of tumor progression and immunosuppressive microenvironments | Molecular Cancer | Springer Nature Link

Original Source(s)

The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy

  • by Lan Zhang, Mengshu You, Bin Yan, Jian Zhang, Yi Yao, Qingyan Zhang, Zuozhong Xie, Shixiang Wang, Qian Gao

  • September 9, 2026

Related Content

CAR T Before Surgery Improves Glioblastoma Control in Mice

Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

  • September 7, 2026

  • 3 min
The Circadian Skin: Chronobiology as a New Frontier in Dermatological Therapy

Case Report: Possible spatially-distinct de novo invasive cervical carcinoma in the setting of isolated persistent HPV16 after ALA-PDT-mediated histological clearance of CIN3